Pliant Therapeutics, Inc.
PLRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001746473
No open-market purchases or sales by Pliant Therapeutics, Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $54.8M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Pliant Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 81 | 77 | −4 |
| Shares | 30.7M | 30.4M | −310.5K (−1.0%) |
| Value | $893.6M | $512.8M | −$380.8M (−42.6%) |
New holders (7)
Institutions that held Pliant Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 30,000 | $506.0K | 0.00% |
| Walleye Capital LLC | 28,685 | $484.0K | 0.01% |
| Gsa Capital Partners LLP | 25,867 | $437.0K | 0.04% |
| Susquehanna Fundamental Investments, LLC | 11,936 | $201.0K | 0.00% |
| SG Americas Securities, LLC | 11,225 | $189.0K | 0.00% |
| Exane Derivatives | 2,971 | $48.9K | 0.01% |
| Lindbrook Capital, LLC | 700 | $12.0K | 0.00% |
Sold out (11)
Institutions that held Pliant Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Farallon Capital Management, L.L.C. | 490,000 | $14.3M |
| Price T Rowe Associates Inc | 210,678 | $6.13M |
| Sphera Funds Management Ltd. | 51,000 | $1.49M |
| ExodusPoint Capital Management, LP | 14,499 | $422.0K |
| Boothbay Fund Management, LLC | 13,585 | $396.0K |
| TD Asset Management Inc | 14,442 | $292.0K |
| Voya Investment Management LLC | 9,905 | $288.0K |
| Credit Suisse AG | 7,464 | $216.0K |
| Nisa Investment Advisors, LLC | 1,400 | $41.0K |
| Advisor Group Holdings, Inc. | 150 | $4.00K |
| Captrust Financial Advisors | 76 | $2.00K |